50-year Wall Street legend: “Sell this tech stock NOW”

Something very strange is happening to U.S. stocks following President Trump's victory... And this could spell disaster for some of America's favorite tech companies.

You can watch for it for free, right here.

Karen Kaucic Biography and Net Worth

Insider of PPD

Karen Kaucic serves as Executive Vice President and President of Evidera, Chief Medical Officer of the Company. Karen Kaucic has served in various leadership positions at the Company or its predecessor, Jaguar Holding Company I, since December 2009 and currently serves as our executive vice president and president of Evidera, chief medical officer. Prior to joining the Company, Ms. Kaucic held positions in oncology clinical development at AstraZeneca PLC (AZN) from June 2006 to December 2009.

What is Karen Kaucic's net worth?: The estimated net worth of Karen Kaucic is at least $396,773.76 as of September 29th, 2020. Ms. Kaucic owns 8,392 shares of PPD stock worth more than $396,774 as of November 23rd. This net worth evaluation does not reflect any other investments that Ms. Kaucic may own. Learn More about Karen Kaucic's net worth.
How do I contact Karen Kaucic?: The corporate mailing address for Ms. Kaucic and other PPD executives is 929 NORTH FRONT STREET, WILMINGTON NC, 28401. PPD can also be reached via phone at 910-251-0081 and via email at [email protected]. Learn More on Karen Kaucic's contact information.
Has Karen Kaucic been buying or selling shares of PPD?: Karen Kaucic has not been actively trading shares of PPD in the last ninety days. Most recently, Karen Kaucic sold 20,574 shares of the business's stock in a transaction on Tuesday, September 29th. The shares were sold at an average price of $34.80, for a transaction totalling $715,975.20. Following the completion of the sale, the insider now directly owns 8,392 shares of the company's stock, valued at $292,041.60. Learn More on Karen Kaucic's trading history.
Who are PPD's active insiders?: PPD's insider roster includes Glen Donovan (CAO), Ronald Garrow (Insider), Colin Hill (Director), David Johnston (Insider), Karen Kaucic (Insider), and David Simmons (CEO). Learn More on PPD's active insiders.

Karen Kaucic Insider Trading History at PPD

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
9/29/2020	Sell	20,574	$34.80	$715,975.20	8,392

Karen Kaucic Buying and Selling Activity at PPD

PPD Company Overview

PPD, Inc., together with its subsidiaries, provides drug development services to the biopharmaceutical industry worldwide. The company operates through two segments, Clinical Development Services and Laboratory Services. It offers clinical development services, including product development and consulting, early development, Phases II-IV clinical trial management, accelerated enrollment, peri-and post-approval, and medical communications services. The company also provides laboratory services comprising bioanalytical, biomarker, vaccine science, good manufacturing practice, and central laboratory services. It serves pharmaceutical, biotechnology, medical device, and government organizations, as well as other industry participants. The company has a collaboration with Science 37 to design, build, test, implement, and execute digital trials using Science 37's DCT SaaS-based technology platform. PPD, Inc. was founded in 1985 and is headquartered in Wilmington, North Carolina.

Today's Range

Now: $47.28

$47.28

50 Day Range

MA: $47.27

$47.10

$47.41

2 Week Range

Now: $47.28

$31.54

$47.41

Volume

N/A

Average Volume

1,905,567 shs

Market Capitalization

$16.61 billion

P/E Ratio

47.28

Dividend Yield